Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  Takeda Pharmaceutical Company Limited    4502   JP3463000004

TAKEDA PHARMACEUTICAL COMPANY LIMITED

(4502)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Takeda Pharmaceutical Company Limited : half-yearly earnings release

10/26/2020 | 09:15am EST

The company will report its earnings for S1 2020 on 10/29/2020. Generally, the company reports earnings better than estimates. In recent months, the 10 analysts from Standard & Poor's consensus have not revised their EPS estimates.


© MarketScreener.com 2020
All news about TAKEDA PHARMACEUTICAL COMPANY LIMITED
09:53aTAKEDA PHARMACEUTICAL : Announcement of Making Nihon Pharmaceutical Co., Ltd. a ..
AQ
11/24TAKEDA PHARMACEUTICAL : Announcement of Making Nihon Pharmaceutical Co., Ltd. a ..
PU
11/17XOMA : Earns $2 Million Milestone from Takeda as Mezagitamab Advances into Phase..
AQ
11/16TAKEDA PHARMACEUTICAL : Final Results from the Phase 3 HELP Study Open-Label Ext..
AQ
11/16Japan shares close at 29-year high on GDP rebound, vaccine race
RE
11/15Vaccine optimism, GDP data boost Japan stocks to 29-year high
RE
11/13TAKEDA PHARMACEUTICAL : Final Results from the Phase 3 HELP Study™ Open-La..
BU
11/09TAKEDA PHARMACEUTICAL : to Highlight Research Commitment in Bleeding Disorders a..
BU
11/05Japan's Takeda eyes new focus on vaccines after OTC asset sales - CEO
RE
11/05TAKEDA PHARMACEUTICAL : Eligible patients living with rare debilitating genetic ..
AQ
More news
Financials
Sales 2021 3 239 B 31 063 M 31 063 M
Net income 2021 187 B 1 798 M 1 798 M
Net Debt 2021 3 859 B 37 007 M 37 007 M
P/E ratio 2021 36,7x
Yield 2021 4,88%
Capitalization 5 766 B 55 100 M 55 287 M
EV / Sales 2021 2,97x
EV / Sales 2022 2,76x
Nbr of Employees 47 495
Free-Float 99,1%
Chart TAKEDA PHARMACEUTICAL COMPANY LIMITED
Duration : Period :
Takeda Pharmaceutical Company Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TAKEDA PHARMACEUTICAL COMPANY LIMITED
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 14
Average target price 5 297,86 JPY
Last Close Price 3 688,00 JPY
Spread / Highest target 76,2%
Spread / Average Target 43,7%
Spread / Lowest Target 11,2%
EPS Revisions
Managers
NameTitle
Christophe Weber President, CEO & Representative Director
Constantine Saroukos Chief Financial Officer & Director
Andrew S. Plump Director, Research & Development President
Michael E. Mendelsohn Chief Medical & Scientific Officer
Yasuhiko Yamanaka Director
Sector and Competitors
1st jan.Capitalization (M$)
TAKEDA PHARMACEUTICAL COMPANY LIMITED-14.87%54 682
JOHNSON & JOHNSON-1.37%378 744
ROCHE HOLDING AG-4.28%281 946
PFIZER INC.-6.59%203 437
MERCK & CO., INC.-11.89%202 757
NOVARTIS AG-12.66%200 273